Sintx Technologies Inc Stock Price, News & Analysis

SINTX Technologies (NASDAQ:SINT) signed a supply agreement with Evonik on Dec 1, 2025 to manufacture its patented silicon nitride–PEEK (SiN/PEEK) compound for AI‑assisted, 3D‑printed patient‑specific implants. Evonik will produce SiN/PEEK to SINTX specifications at commercial scale, enabling immediate manufacture at SINTX’s U.S. facility.

The compound targets antipathogenic surface behavior, osteogenic support, improved imaging vs standard PEEK, and scalable filament supply for humanitarian vertebral body replacement and future regulatory pathways.

SINTX Technologies (NASDAQ: SINT) reported Q3 2025 results and a business update on November 13, 2025, highlighting a U.S. FDA 510(k) clearance for the SINAPTIC Foot & Ankle Osteotomy Wedge System and first commercial revenue from the private‑labeled OsseoSculpt product. The company said it raised $4.3M in gross proceeds and held $6.25M cash as of September 30, 2025, after executing a sublease expected to save ~$950,000 in lease costs. Q3 financials: revenue $0.2M (vs $0.8M Q3 2024), operating expenses ~$3.4M (down 51% YoY), operating loss $3.4M, net loss $3.5M or $1.19 per diluted share, and adjusted EBITDA loss $2.3M. Near‑term priorities include product launch preparation, KOL engagement, and material extensions into polymer composites.

SINTX Technologies (NASDAQ: SINT) announced the launch and private‑label supply of OsseoSculpt™, a next‑generation biologic designed to complement the company’s FDA 510(k) cleared SINAPTIC® Foot & Ankle Osteotomy Wedge System. Clinical evaluations by multiple design surgeons were completed and SINTX recorded its first commercial revenue in Q3 2025 from early OsseoSculpt orders.

OsseoSculpt features a nanocrystalline HCA surface with biomimetic pore architecture to enhance osteoconduction. The company launched a limited release to select design and early‑adopter sites, with a broader U.S. rollout aligned with wedge availability and surgeon training cycles through Q4 2025–Q1 2026.

SINTX (NASDAQ: SINT) received FDA 510(k) clearance for the SINAPTIC Foot & Ankle Osteotomy Wedge System on October 20, 2025, enabling commercial entry into U.S. reconstructive foot and ankle surgery.

The company plans a U.S. launch in Q1 2026, will leverage U.S.-based manufacturing, and highlights silicon nitride properties including pro-osteogenic effects, bacteriostatic surface behavior (laboratory and animal studies), hydrophilicity, and improved imaging visibility. Industry estimates place the global foot & ankle device market at $4.75–$5.4 billion (2024).

SINTX (NASDAQ: SINT) announced a USPTO Notice of Allowance for a method patent covering its antipathogenic fibrous materials and cited a recently issued U.S. patent No. 12,433,356 (Oct 7, 2025) for the composition. Together, the composition and method patent families expand IP coverage across medical textiles, wound dressings, filtration/PPE, and high-touch clinical surfaces.

The company cites laboratory data showing up to ~99.97% reduction of infectious SARS-CoV-2 in minutes and estimates an addressable market of ~$30B across targeted segments. SINTX plans licensing and co-development deals leveraging both materials and process claims.

SINTX Technologies (NASDAQ: SINT) received a U.S. Patent Notice of Allowance for method claims covering its antipathogenic fabric technology on Oct 14, 2025, expanding IP protection beyond the composition patent (U.S. Patent No. 12,433,356, granted Oct 7, 2025).

This dual patent coverage—composition plus method—targets medical textiles, wound dressings, filtration/PPE and high-touch clinical surfaces and supports licensing and co-development across the company's estimated $30B total addressable market. Company-cited lab data report up to ~99.97% SARS-CoV-2 reduction in minutes for silicon nitride materials; the release notes these are lab results and not cleared device indications. SINTX will pursue licensing, partnerships, and commercialization leveraging the broader IP estate.

SINTX Technologies (NASDAQ: SINT), a company specializing in biomedical applications of silicon nitride, will present at the H.C. Wainwright 27th Annual Global Investment Conference on September 9, 2025 in New York City.

CEO Eric Olson will outline the company's growth strategy, discuss near-term milestones, and explain the impact of their silicon nitride platform in medical device and infection-prevention markets. The presentation will also cover recent financial initiatives, including their warrant inducement plan.

SINTX Technologies (NASDAQ: SINT), a biomedical ceramics company, has announced the successful exercise of warrants resulting in $3.8 million in gross proceeds. The transaction involves the immediate exercise of warrants to purchase 1,099,431 shares at $3.32 per share, originally issued in February 2025.

In exchange for the exercise, the company will issue new unregistered warrants for 1,649,147 shares with an exercise price of $4.79 per share, exercisable immediately with a 5.5-year expiration. H.C. Wainwright & Co. serves as the exclusive placement agent, and SINTX plans to use the proceeds for working capital purposes.

SINTX Technologies (NASDAQ: SINT) has received a USPTO Notice of Allowance for its "Antipathogenic Fibrous Materials" patent application, marking a crucial milestone for its silicon nitride-based antipathogen platform. The patent provides broad protection for using silicon nitride in multiple applications targeting the $30 billion global infection-prevention market.

The technology has demonstrated remarkable efficacy, achieving ~99.97% reduction of multiple coronavirus lineages within 10 minutes and complete inactivation by 30 minutes in laboratory tests. The patent enables applications across medical devices, surgical care, wound management, filtration, PPE, and healthcare infrastructure, addressing the critical challenge of healthcare-associated infections (HAIs) that affect 1 in 31 U.S. hospital patients.

SINTX plans to pursue strategic partnerships and licensing agreements for commercialization, targeting immediate opportunities in wound dressings, surgical drapes, and high-touch clinical environments, with longer-term applications in implant coatings and filtration media.